Action Cannara Biotech - LOVE

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

1,29

Prix Achat

1,28

Prix Vente

1,29

Volume échangé

28 318

1,25 Fourchette du Jour 1,29

0,00 Plage de 52 semaines 0,00

Cap du marché

116,123M

Clôture Veille

1,29

Ouverture

1,28

Dernière Transaction

400

1.29

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

90 018 000

Rendement du Dividende

Ratio Cours sur Bénéfices

18,04

Bénéfice par action (BPA)

0,07

Chiffre d'affairess

82,15M

Bénéfice net

6,44M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.cannara.ca

Siège social

Saint-laurent, Quebec, Can

Fondé

Cannara Biotech Inc est coté dans le secteur Pharmaceutical Preparations de la TSX Venture Exchange avec le ticker LOVE. Le dernier cours de clôture d'Cannara Biotech était de $1,29. Au cours de la dernière année, les actions de Cannara Biotech ont été négociées dans une fourchette de prix de $ 0,00 à $ 0,00.

Cannara Biotech compte actuellement 90 018 000 actions en circulation. La capitalisation boursière d'Cannara Biotech est de $116,12 million. Cannara Biotech a un ratio cours/bénéfice (ratio PE) de 18.04.

Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy

MONTREAL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”...

Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025

Record Revenue: Net revenues of $25.1 million in Q1 2025, a 29% increase compared to $19.5 million in Q1 2024...

Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”...

Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”...

Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market

Record Q4 and year-end total revenues of $23.4 million and $82.2 million, representing a 28% and 43% increase...

Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024

MONTREAL, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE...

Cannara Biotech Reports Q3 2024 Financial Results

Gross cannabis revenues before excise taxes increased to $26.2 million in Q3 2024 from $20.6 million in Q3...

Cannara Biotech Inc. Enters into Definitive Agreement to Acquire TGOD's State-of-the-Art Cultivation and Manufacturing Facility

Cannara Biotech Inc. Enters into Definitive Agreement to Acquire TGOD's State-of-the-Art Cultivation and Manufacturing Facility in...

Cannara Biotech Delivers Strong Q2 2021 Results

Cannara Biotech Delivers Strong Q2 2021 Results Significant second quarter revenue generation of $1.2 million and gross profit...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

LOVE - Frequently Asked Questions (FAQ)

What is the current Cannara Biotech share price?

The current share price of Cannara Biotech is $ 1,29

How many Cannara Biotech shares are in issue?

Cannara Biotech has 90 018 000 shares in issue

What is the market cap of Cannara Biotech?

The market capitalisation of Cannara Biotech is CAD 116,12M

What is the 1 year trading range for Cannara Biotech share price?

Cannara Biotech has traded in the range of $ 0,00 to $ 0,00 during the past year

What is the PE ratio of Cannara Biotech?

The price to earnings ratio of Cannara Biotech is 18,04

What is the cash to sales ratio of Cannara Biotech?

The cash to sales ratio of Cannara Biotech is 1,41

What is the reporting currency for Cannara Biotech?

Cannara Biotech reports financial results in CAD

What is the latest annual turnover for Cannara Biotech?

The latest annual turnover of Cannara Biotech is CAD 82,15M

What is the latest annual profit for Cannara Biotech?

The latest annual profit of Cannara Biotech is CAD 6,44M

What is the registered address of Cannara Biotech?

The registered address for Cannara Biotech is 333 D��CARIE, SUITE 200, SAINT-LAURENT, QUEBEC, H4N 3M9

What is the Cannara Biotech website address?

The website address for Cannara Biotech is www.cannara.ca

Which industry sector does Cannara Biotech operate in?

Cannara Biotech operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
PDVN.PPardus Ventures Inc	$ 0,015 (200,00%)	9,5k
CCDSCarrier Connect Data Solutions Inc	$ 0,15 (200,00%)	42k
KUR.HKure Technologies Inc	$ 0,06 (140,00%)	1 000
ICMIconic Minerals Ltd	$ 0,02 (100,00%)	208k
TVITVI Pacific Inc	$ 0,01 (100,00%)	10,08k
MAHMarksmen Energy Inc	$ 0,005 (-50,00%)	3k
MMNMonarca Minerals Inc	$ 0,005 (-50,00%)	50,54k
AJAAJA Health and Wellness Inc	$ 0,045 (-35,71%)	2k
REEE Tech Resources Inc	$ 0,03 (-33,33%)	149,74k
STUVStuve Gold Corp	$ 0,03 (-33,33%)	16,67k
AMTAmeritrust Financial Technologies Inc	$ 0,07 (40,00%)	7,1M
QNCQuantum Emotion Corp	$ 0,77 (-14,44%)	4,23M
OMGOmai Gold Mines Corp	$ 0,35 (-4,11%)	3,91M
GPUSAlset AI Ventures Inc	$ 0,09 (-10,00%)	3M
SEISintana Energy Inc	$ 0,89 (23,61%)	2,61M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Cannara Biotech Inc (LOVE)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Cannara Biotech Inc

LOVE Dernières nouvelles

Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy

Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025

Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike

Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024

Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market

Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024

Cannara Biotech Reports Q3 2024 Financial Results

Cannara Biotech Inc. Enters into Definitive Agreement to Acquire TGOD's State-of-the-Art Cultivation and Manufacturing Facility

Cannara Biotech Delivers Strong Q2 2021 Results

Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy

Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025

Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike

Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024

Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market

Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024

Cannara Biotech Reports Q3 2024 Financial Results

LOVE - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Cannara Biotech Inc (LOVE) Cours

Cannara Biotech Inc (LOVE)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Cannara Biotech Inc

LOVE Dernières nouvelles

Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy

Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025

Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike

Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024

Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market

Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024

Cannara Biotech Reports Q3 2024 Financial Results

Cannara Biotech Inc. Enters into Definitive Agreement to Acquire TGOD's State-of-the-Art Cultivation and Manufacturing Facility

Cannara Biotech Delivers Strong Q2 2021 Results

Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy

Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025

Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike

Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024

Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market

Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024

Cannara Biotech Reports Q3 2024 Financial Results

LOVE - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS